For the Inventor, By the Inventor

Enter assignee name

Ose Immunotherapeutics

USPTO Granted Patents = 28

CIPO Patents = 4

EPO Patents = 19

Trademarks = 12

Forward Citations = 38

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Nicolas Poirier (21 out of 22 patents)

Caroline Mary (18 out of 20 patents)

Bernard Vanhove (18 out of 22 patents)

4. Vanessa Gauttier (7 out of 7 patents)

5. Virginie Thepenier (7 out of 7 patents)

6. Sabrina Pengam (6 out of 6 patents)

7. Elise Chiffoleau (3 out of 3 patents)

8. Dominique Costantini (3 out of 11 patents)

9. Géraldine Teppaz (2 out of 2 patents)

10. Aurore Morello (2 out of 2 patents)

11. Jean-Pascal Conduzorgues (2 out of 3 patents)

12. Flora Coulon (2 out of 2 patents)

13. José Cohen (1 out of 2 patents)

14. Jean-Paul Soulillou (1 out of 6 patents)

15. Sophie Brouard (1 out of 8 patents)

28 patents: Sort by Forward Citations

1. 12448454 - Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof (2025-10-21),

2. 12371502 - Antibodies directed against CD127 (2025-07-29),

3. 12331118 - Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment (2025-06-17),

4. 12331115 - Uses of anti-SIRPg antibodies (2025-06-17),

5. 12258577 - Method effector cells using anti-CD127 antibodies for applications in cell therapy (2025-03-25),

6. 12252546 - Anti-SIRPa antibodies and their therapeutic applications (2025-03-18),

7. 12091464 - Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1) (2024-09-17),

8. 12077820 - Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients (2024-09-03),

9. 11981713 - Method for manufacturing a stable emulsion for peptide delivery (2024-05-14),

10. 11926671 - Antibodies and polypeptides directed against CD127 (2024-03-12),

11. 11884723 - Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (2024-01-30),

12. 11713356 - Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer (2023-08-01),

13. 11696936 - Treatment of cancer (2023-07-11),

14. 11440964 - Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody (2022-09-13),

15. 11365257 - Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) (2022-06-21),

OSE Immunotherapeutics is a biotechnology company that specializes in the development of innovative immunotherapies for immune-related disorders and cancer. With a focus on activating the immune system's ability to fight diseases, OSE Immunotherapeutics aims to provide novel therapeutic solutions to patients in need. The company leverages its expertise in immunology and proprietary technology platforms to advance a pipeline of promising candidates towards clinical development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

28 Patents

#3 in Nantes

#746 in France

#22,565 in the World

Ose Immunotherapeutics

Forward Citations = 38

23 inventors:

Nicolas Poirier (21 out of 22 patents)

Caroline Mary (18 out of 20 patents)

Bernard Vanhove (18 out of 22 patents)

4. Vanessa Gauttier (7 out of 7 patents)

5. Virginie Thepenier (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…